Rheumatoid ArthritisPhase 3NCT01662063
A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
A Phase 3 study testing Tocilizumab in people with Rheumatoid Arthritis, run by Genentech, Inc. at 79 sites in 2 countries.
Trial summary
This open-label extension study will evaluate the long-term safety and efficacy of SC TCZ in participants with moderate to severe RA who have completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core studies on SC or intravenous (IV) TCZ. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- Tocilizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 218 participants
- Where
- 79 sitesin 2 countries
- Study dates
- Aug 2012to Jun 2014
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core study on SC or IV TCZ and, based on the Investigator's judgment, may continue to benefit from TCZ treatment in this study investigating the SC formulation
- Receiving treatment on an outpatient basis
- Females of childbearing potential and males with female partners of childbearing potential must agree to use reliable means of contraception as defined by protocol
Who cannot join
- Premature withdrawal from WA22762 (NCT01194414) or NA25220 (NCT01232569) core studies for any reason
- History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
- Evidence of serious uncontrolled concomitant disease or disorder
- Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections
- Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening
- History of or currently active primary or secondary immunodeficiency
Show all 11Show fewer
- Oral corticosteroids at greater than (>) 10 mg per day prednisone or equivalent, or non-steroidal anti-inflammatory drugs (NSAIDs) above the maximum recommended dose
- Intra-articular or parenteral corticosteroids within 4 weeks prior to Baseline
- Treatment with any investigational or commercially available biologic disease-modifying anti-rheumatic drug (DMARD) other than TCZ at any time between completion of the core study WA22762 (NCT01194414) or NA25220 (NCT01232569) and enrollment in the long-term extension study
- Pregnant or breastfeeding women
- History of alcohol, drug, or chemical abuse within 1 year prior to Screening
Trial locations and contacts
79 sites in 2 countries.
79 sites in 2 countries
United States78 sites
Study site
Albany, New York, 12206
Study site
Albuquerque, New Mexico, 87102
Study site
Asheville, North Carolina, 28803
Study site
Bethlehem, Pennsylvania, 18015
Study site
Bridgeport, Connecticut, 06606
Study site
Brooklyn, New York, 11201
Study site
Charleston, South Carolina, 29407
Study site
Charlotte, North Carolina, 28210
Study site
Cincinnati, Ohio, 45219
Study site
Clifton, New Jersey, 07012
Study site
Coeur d'Alene, Idaho, 83814
Study site
Denver, Colorado, 80230-7127
Study site
Duncansville, Pennsylvania, 16635
Study site
Eagan, Minnesota, 55121
Study site
Florissant, Missouri, 63031
Study site
Flowood, Mississippi, 39232
Study site
Freehold, New Jersey, 07728
Study site
Fullerton, California, 92835
Study site
Gainesville, Georgia, 30501
Study site
Hagerstown, Maryland, 21740
Study site
Houston, Texas, 77004
Study site
Houston, Texas, 77074
Study site
Idaho Falls, Idaho, 83404
Study site
Jackson, Mississippi, 39202
Study site
Jupiter, Florida, 33458
Study site
Knoxville, Tennessee, 37909
Study site
Lebanon, New Hampshire, 03756
Study site
Lincoln, Nebraska, 68516
Study site
Long Beach, California, 90806
Study site
Los Angeles, California, 90048
Study site
Manalapan, New Jersey, 07726
Study site
Memphis, Tennessee, 38104
Study site
Memphis, Tennessee, 38119
Study site
Meridian, Idaho, 83642
Study site
Monroe, Louisiana, 71203
Study site
Morton Grove, Illinois, 60053
Study site
Nassau Bay, Texas, 77058
Study site
Oklahoma City, Oklahoma, 73103
Study site
Oklahoma City, Oklahoma, 73104
Study site
Olympia, Washington, 98502
Study site
Orchard Park, New York, 14127
Study site
Orlando, Florida, 32806
Study site
Palm Harbor, Florida, 34684
Study site
Peoria, Arizona, 85381
Study site
Perrysburg, Ohio, 43551
Study site
Raleigh, North Carolina, 27615
Study site
Saint Claire Shores, Michigan, 48081
Study site
San Diego, California, 92108
Study site
San Leandro, California, 94578
Study site
Scottsdale, Arizona, 85258
Study site
Seattle, Washington, 98104
Study site
South Miami, Florida, 33143
Study site
Spokane, Washington, 99204
Study site
Springfield, Illinois, 62703
Study site
St Louis, Missouri, 63117
Study site
St Louis, Missouri, 63141
Study site
Tampa, Florida, 33614
Study site
Toledo, Ohio, 43606
Study site
Trumbull, Connecticut, 06611
Study site
Tucson, Arizona, 85704
Study site
Tucson, Arizona, 85715
Study site
Tucson, Arizona, 85723
Study site
Tucson, Arizona, 85724
Study site
Tulsa, Oklahoma, 74135
Study site
Tuscaloosa, Alabama, 35406
Study site
Upland, California, 91786
Study site
Van Nuys, California, 91405
Study site
Venice, Florida, 34233
Study site
Vernon Hills, Illinois, 60061
Study site
Voorhees Township, New Jersey, 08043
Study site
Wenatchee, Washington, 98801
Study site
West Hills, California, 91307
Study site
Wheaton, Maryland, 20902
Study site
Whittier, California, 90606
Study site
Wichita, Kansas, 67208
Study site
Wilmington, North Carolina, 28401
Study site
Worcester, Massachusetts, 01605
Study site
Wyomissing, Pennsylvania, 19610
About this study
Official title: A Multicenter Open-Label, Long-Term Extension Study of WA22762 and NA25220 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
This open-label extension study will evaluate the long-term safety and efficacy of SC TCZ in participants with moderate to severe RA who have completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core studies on SC or intravenous (IV) TCZ. Participants will receive TCZ 162 milligrams (mg) SC every week (QW) or every 2 weeks (Q2W) for up to 96 weeks.
- Conditions
- Rheumatoid Arthritis
- Being tested
- Tocilizumab
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TocilizumabDrug
Also called RoActemra/Actemra
TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
| Study group | Role | What they receive |
|---|---|---|
| SC TCZ QW | Experimental | Participants who received IV TCZ in the previous trial will be switched to SC TCZ 162 mg QW, and those who received SC TCZ will continue at their same dosage of SC TCZ 162 mg QW. Tocilizumab will be given for an additional 96 weeks in this open-label extension study. Receives: Drug: Tocilizumab |
| SC TCZ Q2W | Experimental | Participants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study. Receives: Drug: Tocilizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With at Least One Serious Adverse Event (SAE)
Adverse events (AEs) were monitored throughout treatment. AEs were defined as any untoward medical occurrence in a participant who received study drug regardless of causality. SAEs were defined as AEs that were fatal or life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, manifested as a congenital anomaly/birth defect, were medically significant, or required intervention to prevent any of the aforementioned outcomes. The number of participants with at least one SAE regardless of treatment relationship was reported.
Measured: From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)
Percentage of Participants With at Least One SAE
AEs were monitored throughout treatment. AEs were defined as any untoward medical occurrence in a participant who received study drug regardless of causality. SAEs were defined as AEs that were fatal or life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, manifested as a congenital anomaly/birth defect, were medically significant, or required intervention to prevent any of the aforementioned outcomes. The percentage of participants with at least one SAE regardless of treatment relationship was calculated.
Measured: From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)
Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Any Timepoint
Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated.
Measured: From Baseline to 8 weeks after last dose; assessed at Baseline; Weeks 12, 24, 36, 48, 60, 72, 84, 96; and up to 8 weeks after last dose (up to 2 years overall)
Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Baseline
Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated.
Measured: Baseline
Percentage of Participants With a Positive Anti-TCZ Antibody Assay Post-Baseline
Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated. Positive assay results obtained post-Baseline were further investigated via confirmation assay and a neutralization assay.
Measured: From Week 12 up to 8 weeks after last dose; assessed at Weeks 12, 24, 36, 48, 60, 72, 84, 96; and up to 8 weeks after last dose (up to 2 years overall)
Secondary outcomes (35)
Percentage of Participants Who Correctly Administered All SC TCZ Doses
Compliance was assessed using drug dispensing logs, diary cards kept by the participant, and return records, as reviewed by the Investigator at regular visits. Total compliance up to the end of treatment was defined as the percentage of participants who correctly administered all scheduled doses of SC TCZ. Correct administration was defined as proper injection technique, injection of the correct amount (162 mg), device not left at room temperature for greater than (>) 8 hours, and absence of other medication errors.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Disease Activity Score Based on 28 Joints (DAS28) Score
The DAS28 was calculated using the Swollen Joint Count (SJC), Tender Joint Count (TJC), erythrocyte sedimentation rate (ESR), and Global Assessment of Disease Activity by the participant according to Visual Analog Scale (VAS) score. For the DAS28 formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-millimeter (mm) scale to a 10-point score. The DAS28 was calculated as (0.56 multiplied by [×] square root of TJC) + (0.28 × square root of SJC) + (0.7 × log natural [ln] ESR) + (0.014 × VAS). Scores may range from 0 to 10, where higher scores indicate increased disease activity.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in DAS28 Score
The DAS28 was calculated using the SJC, TJC, ESR, and Global Assessment of Disease Activity by the participant according to VAS score. For the DAS28 formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS). Scores may range from 0 to 10, where higher scores indicate increased disease activity. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.
Measured: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Clinical Disease Activity Index (CDAI) Score
The CDAI was calculated using the SJC, TJC, and Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores. For the CDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The CDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician). Scores may range from 0 to 76, where higher scores indicate increased disease activity.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in CDAI Score
The CDAI was calculated using the SJC, TJC, and Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores. For the CDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The CDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician). Scores may range from 0 to 76, where higher scores indicate increased disease activity. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.
Measured: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Simplified Disease Activity Index (SDAI) Score
The SDAI was calculated using the SJC, TJC, Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores, and high-sensitivity C-reactive protein (hsCRP) level. For the SDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The SDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician) + hsCRP. Because the formula includes hsCRP, scores may theoretically range from 0 to infinity, where higher scores indicate increased disease activity. However, based upon normal hsCRP level within 1 milligram per deciliter (mg/dL), scores would be expected to fall within less than or equal to (≤) 77 points.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in SDAI Score
The SDAI was calculated using the SJC, TJC, Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores, and hsCRP level. For the SDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The SDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician) + hsCRP. Because the formula includes hsCRP, scores may theoretically range from 0 to infinity, where higher scores indicate increased disease activity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.
Measured: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Tender Joint Count (TJC) Score
Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The number of tender joints was taken as the TJC score, where values may range from 0 to 68.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in TJC Score
Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The number of tender joints was taken as the TJC score, where values may range from 0 to 68. The change from Baseline to each visit was calculated, where positive changes represent an increase in number of tender joints.
Measured: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Swollen Joint Count (SJC) Score
Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The number of swollen joints was taken as the SJC score, where values may range from 0 to 66.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in SJC Score
Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The number of swollen joints was taken as the SJC score, where values may range from 0 to 66. The change from Baseline to each visit was calculated, where positive changes represent an increase in number of swollen joints.
Measured: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Number of Participants With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Dose Reduction, Interruption, or Discontinuation
Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Participants With a DMARD Dose Reduction, Interruption, or Discontinuation
Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for DMARD Dose Reduction or Interruption
Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline. The reasons for any DMARD dose reduction/interruption ≤60 days were reported. More than one reason could be given for a single change in DMARD therapy, and each participant could also change DMARD therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for DMARD Discontinuation
Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline. The reasons for any DMARD discontinuation were reported. More than one reason could be given for a single change in DMARD therapy, and each participant could also change DMARD therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Number of Participants With a Corticosteroid (CCS) Dose Reduction, Interruption, or Discontinuation
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Participants With a CCS Dose Reduction, Interruption, or Discontinuation
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for CCS Dose Reduction
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS dose reduction were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for CCS Dose Interruption
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS dose interruption ≤14 days were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for CCS Discontinuation
Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS discontinuation >14 days were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Number of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen
Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The number of participants who switched from the QW to the Q2W regimen and did not return to the QW regimen was reported.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen
Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The percentage of participants who switched from the QW to the Q2W regimen and did not return to the QW regimen was calculated.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Number of Participants Who Returned to the QW Regimen After Switching to the Q2W Regimen
Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The number of participants who switched from the QW to the Q2W regimen and thereafter returned to the QW regimen was reported with the reason for returning to the QW regimen.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Time to Return to the QW Regimen After Switching to the Q2W Regimen
Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. Time to return was defined as the time between switching to the Q2W regimen and returning to the previous QW regimen.
Measured: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Global Assessment of Disease Activity by the Participant According to Visual Analog Scale (VAS) Score
The Global Assessment of Disease Activity was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no disease activity") to 100 mm ("maximum disease activity"), with higher scores representing an increase in perceived symptoms.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in Global Assessment of Disease Activity by the Participant According to VAS Score
The Global Assessment of Disease Activity was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no disease activity") to 100 mm ("maximum disease activity"), with higher scores representing an increase in perceived symptoms. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in perceived disease activity.
Measured: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Global Assessment of Pain by the Participant According to VAS Score
The Global Assessment of Pain was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no pain") to 100 mm ("unbearable pain"), with higher scores representing an increase in pain.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in Global Assessment of Pain by the Participant According to VAS Score
The Global Assessment of Pain was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no pain") to 100 mm ("unbearable pain"), with higher scores representing an increase in pain. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in pain.
Measured: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Heath Assessment Questionnaire-Disability Index (HAQ-DI) Score
The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in HAQ-DI Score
The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability. The change from Baseline to each visit was calculated, where positive changes represent an increased need for assistance with daily activities.
Measured: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Percentage of Participants With HAQ-DI Score <0.5
The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability. The percentage of participants achieving a score <0.5 was calculated at each visit.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Number of Participants With Low Disease Activity According to DAS28, SDAI, and CDAI Criteria
Low disease activity was defined as DAS28 ≤3.2, SDAI ≤11, or CDAI ≤10. For each formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The CDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician), with potential scores from 0 to 76. For all instruments, higher scores indicate increased disease activity. The number of participants who met criteria for low disease activity was reported at each visit.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Percentage of Participants With Low Disease Activity According to DAS28, SDAI, and CDAI Criteria
Low disease activity was defined as DAS28 ≤3.2, SDAI ≤11, or CDAI ≤10. For each formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The CDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician), with potential scores from 0 to 76. For all instruments, higher scores indicate increased disease activity. The percentage of participants who met criteria for low disease activity was calculated at each visit.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Number of Participants With Remission According to DAS28, SDAI, and Boolean Criteria
Remission was defined as DAS28 <2.6, SDAI ≤3.3, or meeting all Boolean criteria (28-count SJC and TJC ≤1, VAS ≤10 mm, and hsCRP ≤1 mg/dL). For DAS28 and SDAI formulas, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. For these instruments, higher scores indicate increased disease activity. The number of participants who met criteria for remission was reported at each visit.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Percentage of Participants With Remission According to DAS28, SDAI, and Boolean Criteria
Remission was defined as DAS28 <2.6, SDAI ≤3.3, or meeting all Boolean criteria (28-count SJC and TJC ≤1, VAS ≤10 mm, and hsCRP ≤1 mg/dL). For DAS28 and SDAI formulas, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. For these instruments, higher scores indicate increased disease activity. The percentage of participants who met criteria for remission was calculated at each visit.
Measured: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2012 (estimated)
- Study startAug 2012
- Primary completionApr 2014
- Study completionJun 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by Genentech, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 218 participants (actual)
Sponsor and investigators
- Lead sponsor
- Genentech, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Genentech, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01662063
- Sponsor's protocol ID
- ML28338
- Status last verified
- Aug 2016
- First submitted
- 30 Jul 2012
- Last updated
- 12 Oct 2016
- Results posted
- Yes, on ClinicalTrials.gov
Publications
Kivitz A, Wallace T, Olech E, Borofsky M, Devenport J, Pei J, Michalska M. Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study. Rheumatol Ther. 2016 Dec;3(2):291-304. doi: 10.1007/s40744-016-0043-1. Epub 2016 Sep 24.
PubMed 27747585
Study at a glance
From the registry record, last updated by the sponsor on 12 Oct 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter Open-Label, Long-Term Extension Study of WA22762 and NA25220 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
- ClinicalTrials.gov ID
- NCT01662063
- Acronym / sponsor ID
- ML28338
- Conditions
- Rheumatoid Arthritis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 218 participants (actual)
- Lead sponsor
- Genentech, Inc.Industry (pharma, biotech, devices)
- Study start
- Aug 2012
- Primary completion
- Apr 2014 (actual)
- Study completion
- Jun 2014 (actual)
- First posted
- 10 Aug 2012 (estimated)
- Results
- Posted 12 Oct 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This open-label extension study will evaluate the long-term safety and efficacy of SC TCZ in participants with moderate to severe RA who have completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core studies on SC or intravenous (IV) TCZ. Participants will receive TCZ 162 milligrams (mg) SC every week (QW) or every 2 weeks (Q2W) for up to 96 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SC TCZ QW | Experimental | Drug: TocilizumabParticipants who received IV TCZ in the previous trial will be switched to SC TCZ 162 mg QW, and those who received SC TCZ will continue at their same dosage of SC TCZ 162 mg QW. Tocilizumab will be given for an additional 96 weeks in this open-label extension study. |
| SC TCZ Q2W | Experimental | Drug: TocilizumabParticipants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core study on SC or IV TCZ and, based on the Investigator's judgment, may continue to benefit from TCZ treatment in this study investigating the SC formulation
- Receiving treatment on an outpatient basis
- Females of childbearing potential and males with female partners of childbearing potential must agree to use reliable means of contraception as defined by protocol
Key exclusion criteria (11 listed)
- Premature withdrawal from WA22762 (NCT01194414) or NA25220 (NCT01232569) core studies for any reason
- History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
- Evidence of serious uncontrolled concomitant disease or disorder
- Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections
- Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TocilizumabAlso: RoActemra/ActemraTCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks. | Drug | SC TCZ Q2W, SC TCZ QW |
Primary outcome
Number of Participants With at Least One Serious Adverse Event (SAE)
Time frame: From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)
Adverse events (AEs) were monitored throughout treatment. AEs were defined as any untoward medical occurrence in a participant who received study drug regardless of causality. SAEs were defined as AEs that were fatal or life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, manifested as a congenital anomaly/birth defect, were medically significant, or required intervention to prevent any of the aforementioned outcomes. The number of participants with at least one SAE regardless of treatment relationship was reported.
Percentage of Participants With at Least One SAE
Time frame: From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)
AEs were monitored throughout treatment. AEs were defined as any untoward medical occurrence in a participant who received study drug regardless of causality. SAEs were defined as AEs that were fatal or life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, manifested as a congenital anomaly/birth defect, were medically significant, or required intervention to prevent any of the aforementioned outcomes. The percentage of participants with at least one SAE regardless of treatment relationship was calculated.
Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Any Timepoint
Time frame: From Baseline to 8 weeks after last dose; assessed at Baseline; Weeks 12, 24, 36, 48, 60, 72, 84, 96; and up to 8 weeks after last dose (up to 2 years overall)
Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated.
Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Baseline
Time frame: Baseline
Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated.
Percentage of Participants With a Positive Anti-TCZ Antibody Assay Post-Baseline
Time frame: From Week 12 up to 8 weeks after last dose; assessed at Weeks 12, 24, 36, 48, 60, 72, 84, 96; and up to 8 weeks after last dose (up to 2 years overall)
Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated. Positive assay results obtained post-Baseline were further investigated via confirmation assay and a neutralization assay.
35 secondary outcomes
Percentage of Participants Who Correctly Administered All SC TCZ Doses
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Disease Activity Score Based on 28 Joints (DAS28) Score
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in DAS28 Score
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Clinical Disease Activity Index (CDAI) Score
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in CDAI Score
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Simplified Disease Activity Index (SDAI) Score
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in SDAI Score
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Tender Joint Count (TJC) Score
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in TJC Score
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Swollen Joint Count (SJC) Score
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in SJC Score
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Number of Participants With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Dose Reduction, Interruption, or Discontinuation
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Participants With a DMARD Dose Reduction, Interruption, or Discontinuation
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for DMARD Dose Reduction or Interruption
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for DMARD Discontinuation
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Number of Participants With a Corticosteroid (CCS) Dose Reduction, Interruption, or Discontinuation
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Participants With a CCS Dose Reduction, Interruption, or Discontinuation
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for CCS Dose Reduction
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for CCS Dose Interruption
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Reasons Given for CCS Discontinuation
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Number of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Percentage of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Number of Participants Who Returned to the QW Regimen After Switching to the Q2W Regimen
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Time to Return to the QW Regimen After Switching to the Q2W Regimen
Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Global Assessment of Disease Activity by the Participant According to Visual Analog Scale (VAS) Score
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in Global Assessment of Disease Activity by the Participant According to VAS Score
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Global Assessment of Pain by the Participant According to VAS Score
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in Global Assessment of Pain by the Participant According to VAS Score
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Heath Assessment Questionnaire-Disability Index (HAQ-DI) Score
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Change From Baseline in HAQ-DI Score
Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Percentage of Participants With HAQ-DI Score <0.5
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Number of Participants With Low Disease Activity According to DAS28, SDAI, and CDAI Criteria
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Percentage of Participants With Low Disease Activity According to DAS28, SDAI, and CDAI Criteria
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Number of Participants With Remission According to DAS28, SDAI, and Boolean Criteria
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Percentage of Participants With Remission According to DAS28, SDAI, and Boolean Criteria
Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Oct 2016.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 27747585Kivitz A, Wallace T, Olech E, Borofsky M, Devenport J, Pei J, Michalska M. Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study. Rheumatol Ther. 2016 Dec;3(2):291-304. doi: 10.1007/s40744-016-0043-1. Epub 2016 Sep 24.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Genentech, Inc.
79 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Tocilizumab in people with Rheumatoid Arthritis, run by Genentech, Inc. at 79 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Oct 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 79 sites in United States, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 Oct 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With at Least One Serious Adverse Event (SAE) (time frame: From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01662063, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Oct 2016.